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Should the Ross procedure be considered in infective aortic valve endocarditis? 
Invited Commentary: 
Loobuyck and colleagues1 report their experience of the Ross operation to assess the suitability 
of this procedure in the setting of active aortic valve endocarditis. Over a 27-year period, they 
performed 38 Ross procedures (1.4 cases per annum) for active endocarditis in a population with 
mean age of 33.9 years. They report good outcomes with an operative mortality of 5.3% in this 
unusually young group of patients. The incidence of perioperative neurological deficit was not 
reported. To avoid the problem of autograft dilatation, a disadvantage of the Ross procedure, the 
authors have modified their technique by placing the autograft inside a prosthetic vascular graft 
in some of their patients. Whilst this may prevent dilatation of the autograft, leaving a prosthetic 
graft in a patient with active endocarditis may have implications for recurrent infection and 
possible future re-do surgery.  
The Ross procedure has the advantage of avoiding prosthetic material in the aortic 
position, with excellent haemodynamics, the theoretical reduced risk of infection as well as 
avoidance of anticoagulation. By using prosthetic material around the autograft, Loobuyck and 
colleagues counteract the benefits of avoiding possible reinfection. The authors rightly state that 
the procedure is rarely performed in the context of infective endocarditis. The Ross operation is 
not the first line treatment for infective endocarditis. Use of tissue valve, homograft or 
mechanical valve are the standard of care. Homograft has been considered an attractive 
alternative to prosthetic valve replacement, especially in the setting of aortic root abscess, 
dehiscence of the aorto-mitral continuity and disruption of the left ventricular outflow tract. It 
has a low incidence of reoperation for recurrent infection and good outcomes with peri-annular 
infection 2. The debate about the ideal choice of valve in patients with aortic valve endocarditis 
 2
has been addressed in a recent meta-analysis by Flynn and colleagues 3. In their analysis of 4393 
patients, where 2336 and 2057 patients received mechanical or bioprosthetic valve respectively, 
there was no statistically significant difference in survival, reoperation for structural valve 
deterioration or recurrent endocarditis with one of the studies reporting follow up to 15 years. In 
addition, use of homograft did not confer any advantage regarding prevention of recurrence of 
infection over other valves 4. Kim and colleagues reported 304 consecutive patients undergoing 
surgery for aortic valve endocarditis with 86 undergoing homograft, 139 undergoing mechanical 
and 79 undergoing tissue valve replacements. There was a significant difference in age between 
the groups, with those receiving tissue valves being older, mean age 59.8 years, versus 47.2 years 
and 55.6 years for mechanical and homograft valves respectively. At a median follow up of 29.4 
months, there was no significant benefit in reinfection, reoperation for valve deterioration or 
survival.  
Loobuyck and colleagues1 hould be commended for demonstrating the feasibility of the 
Ross in infective endocarditis in an unusually young cohort. However, for endocarditis, tissue or 
mechanical aortic valve replacement remain the standard of care with homograft aortic root 
replacement reserved for those with significant periannular and sub-annular involvement.  
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